MALVERN, PA — YPrime was named among Everest Group’s Top 50 Pharmaceutical Technology Providers for 2026, as the clinical-trial technology company expands its use of artificial intelligence to reduce study-development work while maintaining the controls required in regulated pharmaceutical research.
Everest Group’s annual ranking evaluates technology providers across pharmaceutical development and commercialization based on adoption, market impact and scale. The research firm cited YPrime’s electronic clinical outcome assessment, or eCOA, interactive response technology, or IRT, and electronic consent products.
YPrime’s technology supports clinical studies in more than 100 countries and more than 250 languages, according to the company.
The recognition comes as pharmaceutical companies increasingly seek to connect previously separate clinical-trial systems while introducing AI into workflows governed by regulatory, validation and data-integrity requirements.
“Pharmaceutical enterprises shift from stand-alone workflow digitization toward connected, AI-enabled execution,” Nisarg Shah, vice president at Everest Group, stated. He said YPrime’s configurable eCOA and IRT capabilities, AI work in multilingual localization and partnerships with technology companies and clinical research organizations contributed to its placement.
YPrime has been applying AI to processes that traditionally require substantial manual work. In an analysis covering 15 studies, the company reported that AI-assisted eCOA localization reduced migration errors by 74% compared with traditional migration processes.
The company did not provide additional methodology or underlying data from that analysis in its release.
YPrime has also introduced an AI-powered Calculation Engine intended to accelerate clinical-study configuration while retaining validation, traceability and human oversight.
The company said its platform can reduce eCOA build times to as little as one week for a simple study and five weeks for more complex trials. Those timelines are intended to shorten the period before sponsors can begin enrolling participants.
YPrime’s Participant Hub brings visit schedules, study tasks, guidance and approved training materials into its existing eCOA application rather than requiring clinical sites to administer another participant-facing system.
Chief Executive Officer Ian Lennox said sponsors and clinical research organizations are seeking technology that can reduce operational demands while maintaining confidence in trial data.
“Organizations are looking for partners that can simplify execution, reduce operational burden, and create greater confidence in data that improves study outcomes,” Lennox stated.
The company also provides an in-house global support operation available around the clock for clinical sites and study participants.
The Top 50 placement follows Everest Group’s designation of YPrime as a Leader in its 2025 eCOA PEAK Matrix Assessment. YPrime also received recognition for patient engagement and AI-related clinical-trial technology in 2025.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.